Literature DB >> 28516236

Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study.

Carlos Marras1, Indalecio Monteagudo2, Georgina Salvador3, Francisco J de Toro4, Alejandro Escudero5, Juan J Alegre-Sancho6, Enrique Raya7, Ana Ortiz8, Loreto Carmona9, Yvonne Mestre10, Luis Cea-Calvo10, Jaime Calvo-Alén11.   

Abstract

The ARCO study (Study on Adherence of Rheumatoid Arthritis patients to SubCutaneous and Oral Drugs), a multicenter, non-interventional retrospective study, was primarily designed to assess the percentage of patients [aged ≥18 years with an established rheumatoid arthritis (RA) diagnosis] with non-adherence to prescribed subcutaneous biologicals. This paper reports data for the secondary objective from a subset of patients, namely to evaluate non-adherence to prescribed oral antirheumatic drugs in RA patients in Spain using the validated Compliance Questionnaire Rheumatology (CQR). Patients also completed the Morisky-Green Medication Adherence Questionnaire, Beliefs about Medicines Questionnaire, and a questionnaire (developed and validated in Spain) on patient satisfaction with RA treatment and preferences. A total of 271 patients (76.7% females; mean age 55.6 years) were being treated with oral drugs for RA, of which 234 completed the CQR questionnaire. Non-adherence was reported in 49/234 (20.9%) patients. The proportion of non-adherence in younger patients (aged ≤48 years; 37.5%) was double that recorded in patients aged >48 years (p = 0.006). Patients with a perception of lower efficacy also had a higher risk of non-adherence (p = 0.012). Multivariable analysis showed that younger age and male gender were independently associated with risk of non-adherence. There was only slight agreement between the CQR and Morisky-Green assessment tools (kappa coefficient = 0.186), possibly reflecting the fact that both questionnaires measure slightly different aspects of medication adherence. In conclusion, one out of five RA patients was identified as at risk for non-adherence with the CQR, and this was more frequent in younger patients and in males.

Entities:  

Keywords:  Adherence; Non-adherence; Oral medication; Questionnaire; Rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28516236     DOI: 10.1007/s00296-017-3737-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

Review 2.  The impact of medication regimen factors on adherence to chronic treatment: a review of literature.

Authors:  Karen S Ingersoll; Jessye Cohen
Journal:  J Behav Med       Date:  2008-01-19

3.  Medication adherence: WHO cares?

Authors:  Marie T Brown; Jennifer K Bussell
Journal:  Mayo Clin Proc       Date:  2011-03-09       Impact factor: 7.616

Review 4.  Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review.

Authors:  Annelieke Pasma; Adriaan van't Spijker; Johanna M W Hazes; Jan J V Busschbach; Jolanda J Luime
Journal:  Semin Arthritis Rheum       Date:  2013-01-24       Impact factor: 5.532

Review 5.  Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature.

Authors:  Bart J F van den Bemt; Hanneke E Zwikker; Cornelia H M van den Ende
Journal:  Expert Rev Clin Immunol       Date:  2012-05       Impact factor: 4.473

Review 6.  The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis.

Authors:  Anat Scheiman-Elazary; Lewei Duan; Courtney Shourt; Harsh Agrawal; David Ellashof; M Cameron-Hay; Daniel E Furst
Journal:  J Rheumatol       Date:  2016-02-15       Impact factor: 4.666

7.  Determinants of methotrexate adherence in rheumatoid arthritis patients.

Authors:  Ellen De Cuyper; Veronique De Gucht; Stan Maes; Yoleen Van Camp; Luc S De Clerck
Journal:  Clin Rheumatol       Date:  2016-01-19       Impact factor: 2.980

8.  Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.

Authors:  Sayed H Naderi; Jonathan P Bestwick; David S Wald
Journal:  Am J Med       Date:  2012-06-27       Impact factor: 4.965

Review 9.  Interventions for enhancing medication adherence.

Authors:  R B Haynes; E Ackloo; N Sahota; H P McDonald; X Yao
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

10.  Adherence to treatment in patients with ankylosing spondylitis.

Authors:  Pablo Arturi; Emilce Edith Schneeberger; Fernando Sommerfleck; Emilio Buschiazzo; César Ledesma; José Antonio Maldonado Cocco; Gustavo Citera
Journal:  Clin Rheumatol       Date:  2013-03-21       Impact factor: 2.980

View more
  9 in total

1.  Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011 : A retrospective analysis of 72% of the population.

Authors:  Tanja A Stamm; Berthold Reichardt; Jochen Zwerina; Valentin Ritschl; Valerie Nell-Duxneuner
Journal:  Wien Klin Wochenschr       Date:  2018-02-14       Impact factor: 1.704

2.  Validity and Reliability of the Thai Version of the 19-Item Compliance-Questionnaire-Rheumatology.

Authors:  Saranya Panichaporn; Wanwisa Chanapai; Ananya Srisomnuek; Phakhamon Thaweeratthakul; Wanruchada Katchamart
Journal:  Patient Prefer Adherence       Date:  2022-08-17       Impact factor: 2.314

3.  Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Pongthorn Narongroeknawin; Ngamsiree Sukprasert; Wanwisa Chanapai; Ananya Srisomnuek
Journal:  Clin Rheumatol       Date:  2020-09-21       Impact factor: 2.980

4.  Self-Reported Medication Adherence in Patients With Ankylosing Spondylitis: The Role of Illness Perception and Medication Beliefs.

Authors:  Sena Tolu; Aylin Rezvani; İlhan Karacan; Derya Bugdayci; Habib Can Küçük; Ömer Faruk Bucak; Teoman Aydin
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

5.  Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram.

Authors:  Huijing Wang; Le Zhang; Zhe Liu; Xiaodong Wang; Shikai Geng; Jiaoyu Li; Ting Li; Shuang Ye
Journal:  Patient Prefer Adherence       Date:  2018-09-10       Impact factor: 2.711

6.  Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain.

Authors:  Manuel Pombo-Suarez; Jose Ramon Maneiro Fernandez; Juan Jesus Gomez-Reino
Journal:  Patient Prefer Adherence       Date:  2021-01-26       Impact factor: 2.711

7.  Exploring Factors Influencing Medication Compliance in Saudi Rheumatoid Arthritis Patients: A Nationwide Cross-Sectional Survey - Results from the COPARA Study.

Authors:  Mohammed A Omair; Maha M Alshehri; Nouf A Altokhais; Ghada A Aljanobi; Maha I El Dessougi; Amal AlHarthi; Maha A Omair; Suzan M Attar; Sami M Bahlas; Abdullah S Alfurayj; Mansour S Alazmi; Alhussain M Asiri; Mohammed M AlOmair; Lobna Al Juffali; Haya M Almalag
Journal:  Patient Prefer Adherence       Date:  2022-04-26       Impact factor: 2.711

8.  Quantitation of methotrexate polyglutamates in human whole blood, erythrocytes and leukocytes collected via venepuncture and volumetric absorptive micro-sampling: a green LC-MS/MS-based method.

Authors:  Dala N Daraghmeh; Mahin Moghaddami; Larisa Bobrovskaya; Susanna M Proudman; Michael D Wiese
Journal:  Anal Bioanal Chem       Date:  2022-07-07       Impact factor: 4.478

9.  Predictive validity of the 5-item Compliance Questionnaire for Rheumatology (CQR5) in detecting poor adherence of patients with rheumatoid arthritis to biological medication.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Luca Ceccarelli; Sonia Farah; Daniela Marotto; Valeria Giorgi; Piercarlo Sarzi-Puttini
Journal:  Arthritis Res Ther       Date:  2020-09-29       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.